Divestiture of Preclinical Small Molecule Programs (Details) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	1 Months Ended		12 Months Ended
	Dec. 31, 2024	Mar. 31, 2024	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Disposal Groups, Including Disposal Of Long-Lived Assets [Line Items]
Equity consideration received in the divestiture of small molecule programs (Note 13)			$ 0	$ 15,000	$ 0
Convertible preferred stock, par value (usd per share)	$ 0.01		$ 0.01	$ 0.01
Gain from divestiture of small molecule programs			$ 0	$ 14,537	$ 0
Tenvie Therapeutics, Inc
Disposal Groups, Including Disposal Of Long-Lived Assets [Line Items]
Equity consideration received in the divestiture of small molecule programs (Note 13)		$ 15,000
Noncash or part noncash divestiture, milestone payments, to be received			$ 1,200,000
Future royalties, threshold after first commercial sale			10 years
Gain from divestiture of small molecule programs				$ 14,500
Tenvie Therapeutics, Inc | Series A Preferred Stock
Disposal Groups, Including Disposal Of Long-Lived Assets [Line Items]
Number of shares converted in simple agreement for future equity (in shares)	15.0
Convertible preferred stock, par value (usd per share)	$ 0.0001			$ 0.0001
Fair value of shares converted in simple agreement for future equity	$ 15,000
Fair value of investment	$ 15,000		$ 15,000	$ 15,000